Characterization of Pseudoxanthoma Elasticum

Status Active, not recruiting

Clinical Trial Summary

Pseudoxanthoma elasticum (PXE) is a rare multisystem disorder of autosomal recessive inheritance (OMIM# 264800) and an estimated prevalence between 1:25.000 and 1:100.000. PXE is characterized by calcification and fragmentation of connective tissue rich in elastic fibers. Due to its high content of elastic fibers, Bruch Membrane in eyes of patients affected by PXE becomes thickened and calcified. The ocular phenotype is characterized by angioid streaks and peau d'orange but also choroidal neovascularizations and chorioretinal atrophy thereby in part mimicking the phenotype of age-related macular degeneration. The disease is due to mutations of the ABCC6-gene coding for a transmembrane protein which is mainly expressed in the liver and kidney. It is hypothesized that ABCC6 is involved in the excretion of a yet unknown factor from the liver which inhibits systemic calcification. In animal models several candidates for this factor have been identified but direct evidence for such a factor in patients with PXE is still missing. The primary purpose of this study is to further investigate the ocular phenotype of patients with PXE using multimodal imaging and functional testing to delineate the impact of Bruch membrane pathology on the eye. Furthermore, possible systemic anti-calcification factors, as well as associations with the vascular alterations are investigated to gain more insights into the pathogenesis of PXE..

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pseudoxanthoma Elasticum

Clinical Trial Details

NCT number	NCT02108392
Study type	Observational
Source	University Hospital, Bonn
Contact
Status	Active, not recruiting
Phase
Start date	January 2014
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02537054` - Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)	Phase 2
Completed	`NCT05569252` - A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum	Phase 2
Recruiting	`NCT05662085` - Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Completed	`NCT03070860` - What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum	N/A
Completed	`NCT01446393` - Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)	N/A
Completed	`NCT00470977` - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy	Phase 1/Phase 2
Recruiting	`NCT03758534` - Natural History of GACI With or Without ARHR2 or PXE
Recruiting	`NCT05734196` - The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency	Phase 1
Not yet recruiting	`NCT06462547` - ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency	Phase 2
Recruiting	`NCT01446380` - Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort	N/A
Recruiting	`NCT03813550` - Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)	N/A
Not yet recruiting	`NCT03364504` - Biological Collection of Kidney Cells	N/A
Recruiting	`NCT01731080` - Arterial Wall Calcium Load in Pseudoxanthoma Elasticum	N/A
Completed	`NCT00555113` - Evolution of Visual Impairment During Pseudoxanthoma Elasticum	N/A
Completed	`NCT00341419` - Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Withdrawn	`NCT04441671` - Oral Pyrophosphate Absorption in PXE Disease	Phase 2
Recruiting	`NCT04868578` - PPI Supplementation to Fight ECtopIc Calcification in PXE	N/A
Completed	`NCT05025722` - Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Completed	`NCT01525875` - Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)	Phase 2
Completed	`NCT05246189` - Employment of Patients With Pseudoxanthoma Elasticum